Product
Rezafungin
Aliases
Rezafungin Acetate, Rezafungin for Injection
5 clinical trials
14 indications
Indication
Invasive Fungal InfectionsIndication
Pneumocystis PneumoniaIndication
CandidemiaIndication
MycosisIndication
Fungal InfectionIndication
invasive candidiasisIndication
Fungal sepsisIndication
Invasive CandidiasisIndication
PneumocystisIndication
Mold InfectionIndication
Invasive Fungal DiseaseIndication
AspergillosisIndication
SepsisClinical trial
A Phase 1, Multicentre, Open-Label Study to Evaluate the PK, Safety, and Tolerability of a Single IV Dose of Rezafungin in Paediatric Subjects, Receiving Systemic Antifungals as Prophylaxis for IFI or to Treat a Suspected or Confirmed FIStatus: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 2, Proof-of-Concept, Multicentre, Open-Label, Randomised, Active-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rezafungin Combined With 7 Days of Co-Trimoxazole Versus Co-Trimoxazole Monotherapy in HIV-Infected Adults With Pneumocystis Jirovecii PneumoniaStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisStatus: Completed, Estimated PCD: 2021-10-07
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Pharmacokinetics and Ex Vivo Sequestration of Rezafungin in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)Status: Not yet recruiting, Estimated PCD: 2025-04-01